YTHDC1 and urinary bladder carcinoma: Oppositely, cell viability was reduced in YTHDC1 over‐expressing bladder cancer cells, demonstrated with IC50 for cisplatin reduced from 38.31 ± 7.63 μM in Vector cells to 6.38 ± 5.49 μM in YTHDC1 over‐expressing T24 cells (Figure S2C).